GlobeNewsWire
30 Jun 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Clinical data for the Vida oral appliance showed statistically significant improvement in insomnia severity for 100% of study participants. — Perfect efficacy in a clinical trial for a major medical indication is a powerful catalyst for stock price appreciation and regulatory expansion.
+0.80Vivos intends to expand the Vida appliance's market into the global insomnia and co-morbid insomnia (COMISA) segments. — Entering a multi-billion dollar global market significantly increases the company's Total Addressable Market (TAM) and long-term revenue ceiling.
+0.60The company projects an annual addressable market of approximately $36 million from newly diagnosed insomnia patients at a single site (Sleep Centers of Nevada). — Provides a concrete, though localized, revenue projection that demonstrates the potential scalability of the new treatment modality.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The Vida appliance is already FDA-cleared as a Class II device for other indications, including TMJ and nasal airway dilation. — Existing FDA clearance lowers the regulatory hurdle and operational risk for expanding the device's usage.
+0.30The clinical results were based on a single-site study of 37 adult patients over a period of 3.7 months on average. — The small sample size and single-site nature of the study introduce significant execution risk and the possibility that results may not replicate in larger trials.
-0.20Which stocks this story touches
The company announced positive clinical data for its Vida appliance, potentially opening a major new revenue growth driver in the insomnia market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
14h ago
